Investment Thesis
Eli Lilly demonstrates exceptional fundamental strength with 94.9% net income growth and 37.4% net margin, coupled with robust $4.0B free cash flow generation. The 49.3x interest coverage ratio provides substantial financial flexibility to manage $39.4B debt while investing in growth.
Strengths
- Exceptional profitability with 44.7% operating margin and 37.4% net margin, among the best in pharmaceutical industry
- Accelerating earnings growth of 94.9% YoY combined with 44.7% revenue growth indicates strong operational leverage
- Outstanding free cash flow generation of $4.0B with 20.1% FCF margin, providing ample resources for R&D, acquisitions, and debt service
- Fortress-like interest coverage of 49.3x demonstrates ability to easily service debt despite D/E of 1.26x
- Strong liquidity position with 1.50x current ratio and $5.3B cash reserves providing financial flexibility
Risks
- Significant debt load of $39.4B creates refinancing risk if borrowing costs rise materially in higher rate environment
- Extraordinarily rapid net income growth of 94.9% may not be sustainable long-term and could reflect favorable product mix, one-time items, or cyclical factors
- Heavy dependence on pharmaceutical pipeline execution; any regulatory rejections or competitive pressures could substantially impact future revenue growth trajectories
Key Metrics to Watch
- Revenue and earnings growth rates over next 2-3 quarters to confirm sustainability of 44-95% growth
- Free cash flow consistency and debt reduction trajectory to assess deleveraging progress
- Operating margin stability as company scales to confirm profitability improvements are structural, not temporary
Financial Metrics
Revenue
19.8B
Net Income
7.4B
EPS (Diluted)
$8.26
Free Cash Flow
4.0B
Total Assets
116.6B
Cash
5.3B
Profitability Ratios
Gross Margin
N/A
Operating Margin
44.7%
Net Margin
37.4%
ROE
23.7%
ROA
6.3%
FCF Margin
20.1%
Balance Sheet & Liquidity
Current Ratio
1.50x
Quick Ratio
1.10x
Debt/Equity
1.26x
Debt/Assets
0.0%
Interest Coverage
49.28x
Long-term Debt
39.4B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T18:10:46.587068 |
Data as of: 2026-03-31 |
Powered by Claude AI